Losartan Dosing and Sex‑Specific Considerations

Short answer: Routine losartan dosing does not need adjustment based on sex. Although women may have higher plasma levels of losartan, the active metabolite exposure is similar between men and women, so standard dosing is appropriate. ^{[1] [2]} However, there are critical sex‑specific cautions: losartan (an angiotensin receptor blocker) should not be used during pregnancy and should be stopped immediately if pregnancy occurs; women of childbearing potential should be counseled about these risks and discuss treatment plans before conception. ^{[3] [4]}

---

Dosing and Pharmacokinetics by Sex

• No routine sex-based dose adjustment: In clinical pharmacology summaries for losartan tablets, plasma concentrations of losartan were about twice as high in female hypertensive patients compared to males, but concentrations of the active metabolite were similar in both sexes; therefore, no dosage adjustment is necessary. ^[1] This finding is consistently reported across labeling and applies to adults of varying ages. ^[2]

• Consistency across products: Oral suspension labeling shows the same pattern higher parent drug levels in females, similar active metabolite levels and reiterates that no dose change is needed. ^[5] Thus, standard initiation and titration protocols remain appropriate regardless of sex. ^[6]

---

Pregnancy and Women of Childbearing Potential

• Contraindicated in pregnancy: Losartan can cause serious fetal harm, particularly in the second and third trimesters, including fetal kidney injury and low amniotic fluid (oligohydramnios). ^[4] Patients who become pregnant while taking losartan should stop it immediately and contact their clinician. ^[4]

• Pre‑conception counseling: Women of childbearing age should be advised about the consequences of exposure during pregnancy and discuss alternative treatments if they plan to become pregnant. ^[3] They should be instructed to report pregnancies to their clinician as soon as possible. ^[7]

• Evidence from exposed pregnancies: Case series of ARB exposure in pregnancy have described oligohydramnios, preterm delivery, and transient neonatal renal dysfunction, underscoring the fetal risk when exposure continues into mid‑pregnancy. ^[8] Broader analyses show that persistent oligohydramnios with renin‑angiotensin system blocker exposure portends a poor fetal renal prognosis. ^[9]

---

Practical Guidance

• For women not planning pregnancy: Standard losartan dosing can be used without sex-based adjustment, with routine monitoring similar to men. ^[1] Pharmacokinetic differences in the parent compound do not translate into a need for different doses. ^[2]

• For women planning pregnancy or who may become pregnant: Discuss switching to pregnancy‑compatible antihypertensives before conception; do not continue losartan once pregnancy is confirmed. ^[3] Counseling should explicitly cover second/third‑trimester risks and the need to report pregnancy early. ^[7]

• If exposure occurs: When ARBs are taken during pregnancy, clinicians may monitor amniotic fluid and fetal markers; adverse outcomes are more likely when oligohydramnios persists. ^[9] Stopping the drug early in pregnancy may reduce risk, but prompt specialist evaluation is still warranted. ^[8]

---

Key Points Summary

• Dose adjustment by sex: Not needed; active metabolite exposure is similar in men and women. ^{[1] [2]}
• Pregnancy risk: Do not use in pregnancy; stop immediately if pregnant. ^[4]
• Counseling for childbearing potential: Advise about risks, plan alternatives if pregnancy is intended, and report any pregnancy promptly. ^{[3] [7]}

---

Comparison Table: Sex Differences and Pregnancy Cautions

Topic	Men	Women (non‑pregnant)	Women (pregnant or planning)
Losartan dose adjustment	No adjustment needed. [1]	No adjustment needed; higher parent drug levels but similar active metabolite exposure. [1] [2]	Contraindicated in pregnancy; switch before conception and stop immediately if pregnant. [4] [3] [7]
Pharmacokinetics note	Standard exposure	~2x higher losartan parent plasma levels; active metabolite similar. [1]	Not applicable (avoid use)
Counseling emphasis	Routine ARB counseling	Add pregnancy risk counseling and contraception/planning discussions as appropriate. [3] [7]	Urgent discontinuation and obstetric evaluation; consider fetal monitoring if exposure occurred. [4] [9] [8]

---

Additional Considerations

• Race/ethnicity: Pharmacokinetic differences due to race have not been adequately studied in losartan labeling, so no race-specific dosing guidance is provided. ^[1] This limitation applies across product versions. ^[10]

• Elderly vs. young: Active metabolite and overall exposure are similar, and sex differences do not necessitate dose changes across age groups. ^[2] Standard geriatric precautions (renal function, potassium) still apply. ^[2]

---

Bottom Line

Use standard losartan dosing in both men and women, as no sex-specific adjustment is required. ^[1] Prioritize pregnancy safety: avoid losartan during pregnancy, stop it immediately if pregnancy occurs, and proactively counsel women of childbearing potential about risks and alternatives. ^{[4] [3] [7]}